The guidelines proposed by Kamihara et al. (2017) recommend neuroblastoma screening for patients with CDKN1C variants using abdominal ultrasound, urine vanillylmandelic acid, and homovanillic acid tests with chest X-rays every 3 months until 6 years of age, then every 6 months until 10 years. This evidence concerns the gene CDKN1C and neuroblastoma.